1
|
Moyano LM, Toledo AK, Chirinos J, Vilchez Barreto PMQ, Cavalcanti S, Gamboa R, Ypanaque J, Meza M, Noriega S, Herrera V, Bazan E, Requena A, Silva H, Burgos H, León-Jimenez F. SARS-CoV-2 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave. PLoS Negl Trop Dis 2023; 17:e0010794. [PMID: 37379355 DOI: 10.1371/journal.pntd.0010794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Accepted: 06/06/2023] [Indexed: 06/30/2023] Open
Abstract
BACKGROUND Peru had the second-highest number of COVID-19 cases in Latin America. After the first wave, Peru registered more than 900,000 cases of COVID-19 and more than 36,000 confirmed deaths from the disease. Tumbes, a border area with poor sanitation and not enough water, had the fifth highest death rate. The cross-sectional analytic study aimed: a) to assess seroprevalence of COVID-19 after the first wave; b) to assess sociodemographic determinants and symptoms associated with a positive COVID-19 antibody lateral flow test. METHODOLOGY/PRINCIPAL FINDINGS We performed this study between November 11th and November 30th, 2020, in an informal settlement in Tumbes. Individuals older than two years were invited to participate in a systematic random sample from one in every four households. Finger-prick blood samples were collected, and a census and symptom survey were applied. Within the chosen house, one adult over 18 years of age was chosen for a PCR-RT molecular test. Overall seroprevalence was 25.59%, adjusted seroprevalence was 24.82% (95%CI 22.49-27.25). Women had higher adjusted seroprevalence (28.03% vs 21.11%; 95% CI 24.83-31.41, p = 0.002). Symptoms as fever (PR 1.89: 95% CI 1.44-2.48, p<0.001), general discomfort (PR 1.67; 95% CI 1.23-2.26, p = 0.001), cough (PR 2.0; 95% CI 1.60-2.50, p<0.001), nasal congestion (PR 1.46; 95% CI 1.03-2.09, p = 0.036), respiratory distress (PR 1.64; 95% CI 1.04-2.56, p = 0.031), headache (PR 1.54; 95% CI 1.09-2.17, p = 0.014), anosmia (PR 1.78; 95% CI 1.01-3.14, p = 0.046) and ageusia (PR 2.31; 95% CI 1.48-3.61, p<0.001) were associated with a positive covid-19 antibody lateral flow test. CONCLUSIONS/SIGNIFICANCE The COVID-19 transmission and distribution were highlighted by this cross-sectional study. The data will help the Ministry of Health improve its monitoring, surveillance, and monitoring of respiratory community sequelae in the future.
Collapse
Affiliation(s)
- Luz M Moyano
- Escuela de Medicina Humana, Universidad Cesar Vallejo, Piura, Piura, Peru
- Dirección Regional de Salud de Tumbes, Tumbes, Peru
- Unidad de Medicina Legal I Contralmirante Villar, Tumbes, Peru
| | - Angie K Toledo
- School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru
- Centro de investigación para la preservación de la vida, Lima, Peru
| | - Jenny Chirinos
- School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Percy Mc Quen Vilchez Barreto
- Dirección Regional de Salud de Tumbes, Tumbes, Peru
- Center for Global Health, Universidad Peruana Cayetano Heredia, Tumbes, Peru
| | | | - Ricardo Gamboa
- Dirección Regional de Salud de Tumbes, Tumbes, Peru
- Center for Global Health, Universidad Peruana Cayetano Heredia, Tumbes, Peru
| | - Jhon Ypanaque
- Escuela Profesional de Medicina Humana y Facultad de Ciencias en Salud de la Universidad Nacional de Tumbes, Tumbes, Peru
- Estrategia de enfermedades metaxénicas, Gobierno Regional de Tumbes, Tumbes, Peru
| | - Mauro Meza
- Escuela Profesional de Medicina Humana y Facultad de Ciencias en Salud de la Universidad Nacional de Tumbes, Tumbes, Peru
| | | | | | - Edgar Bazan
- Escuela de Medicina Humana, Universidad Cesar Vallejo, Piura, Piura, Peru
| | - Alexandra Requena
- Escuela Profesional de Medicina Humana y Facultad de Ciencias en Salud de la Universidad Nacional de Tumbes, Tumbes, Peru
| | - Henry Silva
- Escuela Profesional de Medicina Humana y Facultad de Ciencias en Salud de la Universidad Nacional de Tumbes, Tumbes, Peru
| | | | - Franco León-Jimenez
- Hospital Amistad Peru Corea Santa Rosa, II-2 Piura, Peru
- Escuela de Medicina Humana, Universidad Norbert Wiener, Lima, Peru
| |
Collapse
|
2
|
Dub T, Solastie A, Hagberg L, Liedes O, Nohynek H, Haveri A, Virta C, Vara S, Lasander M, Ekström N, Österlund P, Lind K, Valtonen H, Hemmilä H, Ikonen N, Lukkarinen T, Palmu AA, Melin M. High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021. Front Med (Lausanne) 2022; 9:876532. [PMID: 35966873 PMCID: PMC9366099 DOI: 10.3389/fmed.2022.876532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 07/05/2022] [Indexed: 11/13/2022] Open
Abstract
Background Household transmission studies offer the opportunity to assess both secondary attack rate (SAR) and persistence of SARS-CoV-2 antibodies over time. Methods In Spring 2020, we invited confirmed COVID-19 cases and their household members to four visits, where we collected nasopharyngeal and serum samples over 28 days after index case onset. We calculated SAR based on the presence of SARS-CoV-2 neutralizing antibodies (NAb) and assessed the persistence of NAb and IgG antibodies (Ab) against SARS-CoV-2 spike glycoprotein and nucleoprotein. Results SAR was 45% (39/87), including 35 symptomatic secondary cases. During the initial 28-day follow-up, 62% (80/129) of participants developed NAb. Of those that seroconverted, 90% (63/70), 85% (63/74), and 78% (45/58) still had NAb to early B-lineage SARS-CoV-2 3, 6, and 12 months after the onset of the index case. Anti-spike IgG Ab persisted in 100% (69/69), 97% (72/74), and 93% (55/59) of seroconverted participants after 3, 6, and 12 months, while anti-nucleoprotein IgG Ab levels waned faster, persisting in 99% (68/69), 78% (58/74), and 55% (39/71) of participants, respectively. Conclusion Following detection of a COVID-19 case in a household, other members had a high risk of becoming infected. NAb to early B-lineage SARS-CoV-2 persisted for at least a year in most cases.
Collapse
Affiliation(s)
- Timothée Dub
- Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Anna Solastie
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
- *Correspondence: Anna Solastie,
| | - Lotta Hagberg
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Oona Liedes
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Hanna Nohynek
- Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Anu Haveri
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Camilla Virta
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Saimi Vara
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Mervi Lasander
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Nina Ekström
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Pamela Österlund
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Katja Lind
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
- Centre for Military Medicine, Finnish Defence Forces, Helsinki, Finland
| | - Hanna Valtonen
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Heidi Hemmilä
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
- Centre for Military Medicine, Finnish Defence Forces, Helsinki, Finland
| | - Niina Ikonen
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| | - Timo Lukkarinen
- Health Stations and Internal Medicine Clinic, Social and Health Care Sector, Helsinki, Finland
| | - Arto A. Palmu
- Department of Public Health Solutions, Finnish Institute for Health and Welfare, Tampere, Finland
| | - Merit Melin
- Expert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
| |
Collapse
|
4
|
Bhatt M, Plint AC, Tang K, Malley R, Huy AP, McGahern C, Dawson J, Pelchat M, Dawson L, Varshney T, Arnold C, Galipeau Y, Austin M, Thampi N, Alnaji F, Langlois MA, Zemek RL. Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study. CMAJ Open 2022; 10:E357-E366. [PMID: 35414597 PMCID: PMC9007444 DOI: 10.9778/cmajo.20220026] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND Household transmission contributes to SARS-CoV-2 spread, but the role of children in transmission is unclear. We conducted a study that included symptomatic and asymptomatic children and adults exposed to SARS-CoV-2 in their households with the objective of determining how SARS-CoV-2 is transmitted within households. METHODS In this case-ascertained antibody-surveillance study, we enrolled households in Ottawa, Ontario, in which at least 1 household member had tested positive for SARS-CoV-2 on reverse transcription polymerase chain reaction testing. The enrolment period was September 2020 to March 2021. Potentially eligible participants were identified if they had tested positive for SARS-CoV-2 at an academic emergency department or affiliated testing centre; people who learned about the study through the media could also self-identify for participation. At least 2 participants were required for a household to be eligible for study participation, and at least 1 enrolled participant per household had to be a child (age < 18 yr). Enzyme-linked immunosorbent assays were used to evaluate SARS-CoV-2-specific IgA, IgM and IgG against the spike-trimer and nucleocapsid protein. The primary outcome was household secondary attack rate, defined as the proportion of household contacts positive for SARS-CoV-2 antibody among the total number of household contacts participating in the study. We performed descriptive statistics at both the individual and household levels. To estimate and compare outcomes between patient subgroups, and to examine predictors of household transmission, we fitted a series of multivariable logistic regression with robust standard errors to account for clustering of individuals within households. RESULTS We enrolled 695 participants from 180 households: 180 index participants (74 children, 106 adults) and 515 of their household contacts (266 children, 249 adults). A total of 487 household contacts (94.6%) (246 children, 241 adults) had SARS-CoV-2 antibody testing, of whom 239 had a positive result (secondary attack rate 49.1%, 95% confidence interval [CI] 42.9%-55.3%). Eighty-eight (36.8%, 95% CI 29.3%-43.2%) of the 239 were asymptomatic; asymptomatic rates were similar for children (51/130 [39.2%, 95% CI 30.7%-48.5%]) and adults (37/115 [32.2%, 95% CI 24.2%-41.4%]) (odds ratio [OR] 1.3, 95% CI 0.8-2.1). Adults were more likely than children to transmit SARS-CoV-2 (OR 2.2, 95% CI 1.3-3.6). The odds of transmission from asymptomatic (OR 0.6, 95% CI 0.2-1.4) versus symptomatic (OR 0.9, 95% CI 0.6-1.4) index participants to household contacts was uncertain. Predictors of household transmission included household density (number of people per bedroom), relationship to index participant and number of cases in the household. INTERPRETATION The rate of SARS-CoV-2 transmission within households was nearly 50% during the study period, and children were an important source of spread. The findings suggest that children are an important driver of the COVID-19 pandemic; this should inform public health policy.
Collapse
Affiliation(s)
- Maala Bhatt
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont.
| | - Amy C Plint
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Ken Tang
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Richard Malley
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Anne Pham Huy
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Candice McGahern
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Jennifer Dawson
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Martin Pelchat
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Lauren Dawson
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Terry Varshney
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Corey Arnold
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Yannick Galipeau
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Michael Austin
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Nisha Thampi
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Fuad Alnaji
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Marc-André Langlois
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| | - Roger L Zemek
- Department of Pediatrics (Bhatt, Plint, Pham Huy, Varshney, Thampi, Alnaji, Zemek), Children's Hospital of Eastern Ontario, University of Ottawa; Department of Emergency Medicine (Plint, Alnaji, Zemek), University of Ottawa; Children's Hospital of Eastern Ontario Research Institute (Tang, McGahern, J. Dawson, L. Dawson, Austin), Ottawa, Ont.; Division of Infectious Diseases (Malley), Boston Children's Hospital and Harvard Medical School, Boston, Mass.; Department of Biochemistry, Microbiology and Immunology (Pelchat, Arnold, Galipeau, Langlois), Faculty of Medicine, University of Ottawa; University of Ottawa Centre for Infection, Immunity and Inflammation (Pelchat, Langlois); Ottawa Hospital Research Institute (Austin), Ottawa, Ont
| |
Collapse
|